Autopsy report · NCT05384379

Efficacy and Safety Evaluation of BZ371B in ARDS Patients

“Suboptimal enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Biozeus Biopharmaceutical S.A.

Sponsor type

Industry

Conditions

ARDS; ARDS, Human; Pulmonary Disease

Interventions

Inhaled BZ371B

Participants

1

Sites

1

Countries

Brazil

Trials that died the same way

• Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
  “low-rate of enrollment” (72% match in meaning)
• Miromatrix Biological Mesh for Ventral Hernia Repair
  “enrollment rate” (72% match in meaning)
• Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
  “Low enrollment” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.